Machine learning-assisted prognosis prediction and surgical decision-making for glioblastoma: perceived benefits and concerns of patients, caregivers, and neurosurgeons - Top-Institutions - MDSpire

Machine learning-assisted prognosis prediction and surgical decision-making for glioblastoma: perceived benefits and concerns of patients, caregivers, and neurosurgeons

  • By

  • Meredith V. Parsons

  • Olivia Buckley

  • Hamasa Ebadi

  • Eric Leuthardt

  • Tristan McIntosh

  • July 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Washington University School of Medicine
    Washington University School of Medicine

    St. Louis, MO

    Key Differentiators

    • Neurosurgery

  • #2

    Nagoya University Graduate School of Medicine
    Nagoya University Graduate School of Medicine

    Nagoya, Aichi

    Key Differentiators

    • Neurosurgery

  • #3

    Japan Association of Spine Surgeons With Ambition
    Japan Association of Spine Surgeons With Ambition

    Tokyo, Tokyo

    Key Differentiators

    • Neurosurgery

  • #4

    Oslo University Hospital
    Oslo University Hospital

    Oslo, Oslo

    Key Differentiators

    • Neurosurgery

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neurosurgery

Original Source(s)

Machine learning-assisted prognosis prediction and surgical decision-making for glioblastoma: perceived benefits and concerns of patients, caregivers, and neurosurgeons

  • by Meredith V. Parsons, Olivia Buckley, Hamasa Ebadi, Eric Leuthardt, Tristan McIntosh

  • July 2, 2026

Related Content

Development and internal validation of a prognostic nomogram incorporating F-NLR and HAGR scores in patients with oral squamous cell carcinoma: a single-center retrospective cohort study

Smartphones Spot Ocular Malignancies

Could a smartphone-based AI system bring ocular oncology screening directly into the patient’s home?

  • July 2, 2026

  • 3 min
Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets